Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine

Zhong H, Liu S, Cao F, Zhao Y, Zhou J, Tang F, Peng Z, Li Y, Xu S, Wang C, Yang G, Li ZQ (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Frontiers in Immunology Frontiers Research Foundation / Frontiers Media

Book Volume: 12

Article Number: 709986

DOI: 10.3389/fimmu.2021.709986

Abstract

Background: Nowadays, researchers are leveraging the mRNA-based vaccine technology used to develop personalized immunotherapy for cancer. However, its application against glioma is still in its infancy. In this study, the applicable candidates were excavated for mRNA vaccine treatment in the perspective of immune regulation, and suitable glioma recipients with corresponding immune subtypes were further investigated. Methods: The RNA-seq data and clinical information of 702 and 325 patients were recruited from TCGA and CGGA, separately. The genetic alteration profile was visualized and compared by cBioPortal. Then, we explored prognostic outcomes and immune correlations of the selected antigens to validate their clinical relevance. The prognostic index was measured via GEPIA2, and infiltration of antigen-presenting cells (APCs) was calculated and visualized by TIMER. Based on immune-related gene expression, immune subtypes of glioma were identified using consensus clustering analysis. Moreover, the immune landscape was visualized by graph learning-based dimensionality reduction analysis. Results: Four glioma antigens, namely ANXA5, FKBP10, MSN, and PYGL, associated with superior prognoses and infiltration of APCs were selected. Three immune subtypes IS1–IS3 were identified, which fundamentally differed in molecular, cellular, and clinical signatures. Patients in subtypes IS2 and IS3 carried immunologically cold phenotypes, whereas those in IS1 carried immunologically hot phenotype. Particularly, patients in subtypes IS3 and IS2 demonstrated better outcomes than that in IS1. Expression profiles of immune checkpoints and immunogenic cell death (ICD) modulators showed a difference among IS1–IS3 tumors. Ultimately, the immune landscape of glioma elucidated considerable heterogeneity not only between individual patients but also within the same immune subtype. Conclusions: ANXA5, FKBP10, MSN, and PYGL are identified as potential antigens for anti-glioma mRNA vaccine production, specifically for patients in immune subtypes 2 and 3. In summary, this study may shed new light on the promising approaches of immunotherapy, such as devising mRNA vaccination tailored to applicable glioma recipients.

Authors with CRIS profile

Jianguo Zhou Department of Radiation Oncology

Involved external institutions

Wuhan University CN China (CN) University of Mississippi (Ole Miss) US United States (USA) (US) Zunyi Medical University CN China (CN)

How to cite

APA:

Zhong, H., Liu, S., Cao, F., Zhao, Y., Zhou, J., Tang, F.,... Li, Z.Q. (2021). Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.709986

MLA:

Zhong, Hua, et al. "Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine." Frontiers in Immunology 12 (2021).

BibTeX: Download